Therefore, we tested the effects of HER3-VIA using a lapatinib-resistant cell line (rBT474), which we confirmed expresses HER2 and HER3 at similar levels to the BT474 tumor line (Fig. 5a), derived as previously reported [20]. Here, ERBB2 is linked to neoplasm.